QQQ   307.50 (+2.19%)
AAPL   148.76 (+2.29%)
MSFT   258.26 (+2.18%)
META   181.85 (+18.76%)
GOOGL   106.30 (+5.84%)
AMZN   110.17 (+4.77%)
TSLA   187.65 (+3.44%)
NVDA   212.54 (+1.48%)
NIO   11.91 (-1.57%)
BABA   108.96 (-3.42%)
AMD   87.04 (+2.84%)
T   20.11 (-0.35%)
MU   62.42 (-0.29%)
F   14.19 (+2.90%)
CGC   3.09 (+0.32%)
GE   82.34 (+0.02%)
DIS   109.86 (+0.43%)
AMC   6.16 (+7.88%)
PFE   43.78 (-0.43%)
PYPL   86.16 (+3.92%)
NFLX   359.24 (-0.76%)
QQQ   307.50 (+2.19%)
AAPL   148.76 (+2.29%)
MSFT   258.26 (+2.18%)
META   181.85 (+18.76%)
GOOGL   106.30 (+5.84%)
AMZN   110.17 (+4.77%)
TSLA   187.65 (+3.44%)
NVDA   212.54 (+1.48%)
NIO   11.91 (-1.57%)
BABA   108.96 (-3.42%)
AMD   87.04 (+2.84%)
T   20.11 (-0.35%)
MU   62.42 (-0.29%)
F   14.19 (+2.90%)
CGC   3.09 (+0.32%)
GE   82.34 (+0.02%)
DIS   109.86 (+0.43%)
AMC   6.16 (+7.88%)
PFE   43.78 (-0.43%)
PYPL   86.16 (+3.92%)
NFLX   359.24 (-0.76%)
QQQ   307.50 (+2.19%)
AAPL   148.76 (+2.29%)
MSFT   258.26 (+2.18%)
META   181.85 (+18.76%)
GOOGL   106.30 (+5.84%)
AMZN   110.17 (+4.77%)
TSLA   187.65 (+3.44%)
NVDA   212.54 (+1.48%)
NIO   11.91 (-1.57%)
BABA   108.96 (-3.42%)
AMD   87.04 (+2.84%)
T   20.11 (-0.35%)
MU   62.42 (-0.29%)
F   14.19 (+2.90%)
CGC   3.09 (+0.32%)
GE   82.34 (+0.02%)
DIS   109.86 (+0.43%)
AMC   6.16 (+7.88%)
PFE   43.78 (-0.43%)
PYPL   86.16 (+3.92%)
NFLX   359.24 (-0.76%)
QQQ   307.50 (+2.19%)
AAPL   148.76 (+2.29%)
MSFT   258.26 (+2.18%)
META   181.85 (+18.76%)
GOOGL   106.30 (+5.84%)
AMZN   110.17 (+4.77%)
TSLA   187.65 (+3.44%)
NVDA   212.54 (+1.48%)
NIO   11.91 (-1.57%)
BABA   108.96 (-3.42%)
AMD   87.04 (+2.84%)
T   20.11 (-0.35%)
MU   62.42 (-0.29%)
F   14.19 (+2.90%)
CGC   3.09 (+0.32%)
GE   82.34 (+0.02%)
DIS   109.86 (+0.43%)
AMC   6.16 (+7.88%)
PFE   43.78 (-0.43%)
PYPL   86.16 (+3.92%)
NFLX   359.24 (-0.76%)
NASDAQ:CLVS

Clovis Oncology - CLVS Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$0.08
▼
$0.10
50-Day Range
$0.08
▼
$1.09
52-Week Range
$0.08
▼
$3.32
Volume
1.16 million shs
Average Volume
8.88 million shs
Market Capitalization
$11.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Clovis Oncology MarketRank™ Forecast

Analyst Rating
Hold
1.50 Rating Score
Upside/​Downside
6,150.0% Upside
$5.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-1.33
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.68) to ($0.98) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.56 out of 5 stars

Medical Sector

955th out of 1,053 stocks

Pharmaceutical Preparations Industry

466th out of 519 stocks

See Top Rated MarketRank™ Stocks Here

CLVS stock logo

About Clovis Oncology (NASDAQ:CLVS) Stock

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

Receive CLVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clovis Oncology and its competitors with MarketBeat's FREE daily newsletter.

CLVS Stock News Headlines

January 30, 2023 | reuters.com
CLVS.O
January 18, 2023 | seekingalpha.com
CLVSQ Clovis Oncology, Inc.
February 2, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
January 13, 2023 | forbes.com
Clovis Oncology
January 3, 2023 | wsj.com
Firm Retention Summary: Clovis Oncology Inc.
December 12, 2022 | reuters.com
Cancer drugmaker Clovis files for bankruptcy, hit by falling sales
December 12, 2022 | benzinga.com
Thinking about buying stock in Clovis Oncology, Bank of America, Rivian Automotive, Rent the Runway, or Vipshop Holdings?
December 12, 2022 | bizjournals.com
Boulder drugmaker Clovis Oncology files for bankruptcy
February 2, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
December 12, 2022 | finance.yahoo.com
Clovis Plans to Sell Cancer Drug to Novartis in Bankruptcy Deal
December 12, 2022 | finance.yahoo.com
Clovis (CLVS) Files for Bankruptcy Amid Lack of Financial Aid
December 12, 2022 | finance.yahoo.com
Clovis Enters Bankruptcy With Deal to Sell Cancer-Drug Candidate to Novartis
December 12, 2022 | benzinga.com
Cancer Focused Clovis Oncology Files For Bankruptcy
December 12, 2022 | seekingalpha.com
Clovis stock slumps amid Chapter 11 filing, to sell FAP-2286 to Novartis for $50M upfront
December 12, 2022 | marketwatch.com
Clovis Oncology Shares Fall Premarket After Bankruptcy Filing >CLVS
December 12, 2022 | finance.yahoo.com
Clovis Oncology stock slides 10% premarket after company files for bankruptcy
December 12, 2022 | finance.yahoo.com
Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286
December 12, 2022 | finance.yahoo.com
U.S. drugmaker Clovis files for Chapter 11 bankruptcy
December 12, 2022 | finance.yahoo.com
UPDATE 1-Cancer drugmaker Clovis files for bankruptcy, hit by falling sales
November 25, 2022 | finance.yahoo.com
Clovis (CLVS) Stock Down 50% in the Past 6 Months: Here's Why
November 21, 2022 | finance.yahoo.com
Down 67.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Clovis (CLVS)
November 11, 2022 | finance.yahoo.com
Clovis Oncology Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
November 9, 2022 | finance.yahoo.com
Clovis Oncology Shares Nose-Dive As Potential Bankruptcy Filing Looms
November 9, 2022 | finance.yahoo.com
Clovis Oncology stock slides 75% after biotech warns it will run out of cash by January of 2023
November 9, 2022 | reuters.com
Clovis Oncology says could file for bankruptcy in 'very near term'
November 9, 2022 | seekingalpha.com
Clovis Oncology falls 55% on bankruptcy concerns
November 9, 2022 | nasdaq.com
Clovis Oncology Tanks On Possible Bankruptcy Filing
See More Headlines

Receive CLVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clovis Oncology and its competitors with MarketBeat's FREE daily newsletter.

CLVS Company Calendar

Last Earnings
11/09/2022
Today
2/02/2023
Next Earnings (Estimated)
2/22/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CLVS
CUSIP
18946410
CIK
1466301
Web
www.clovisoncology.com
Phone
303-625-5000
Fax
303-245-0360
Employees
N/A
Year Founded
2009

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+6,150.0%
Consensus Rating
Hold
Rating Score (0-4)
1.50
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.83)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-264,520,000.00
Net Margins
-189.37%
Pretax Margin
-189.68%
Return on Equity
N/A
Return on Assets
-57.78%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.14
Quick Ratio
0.12

Sales & Book Value

Annual Sales
$148.76 million
Price / Sales
0.08
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($2.15) per share
Price / Book
-0.04

Miscellaneous

Outstanding Shares
144,955,000
Free Float
138,577,000
Market Cap
$11.60 million
Optionable
Optionable
Beta
0.24

Social Links


Key Executives

  • Mr. Patrick J. Mahaffy MA (Age 55)
    Co-Founder, Chief Exec. Officer, Pres and Exec. Director
  • Dr. Gillian C. Ivers-Read BScDr. Gillian C. Ivers-Read BSc (Age 64)
    Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations
  • Mr. Daniel W. Muehl CPA (Age 54)
    Sr. VP of Fin. and Principal Financial & Accounting Officer
  • Dr. Lindsey Rolfe BSc (Age 50)
    MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance
  • Mr. Corwin Dale Hooks (Age 51)
    Chief Commercial Officer and Sr. VP

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













CLVS Stock - Frequently Asked Questions

Should I buy or sell Clovis Oncology stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last year. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CLVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLVS, but not buy additional shares or sell existing shares.
View CLVS analyst ratings or view top-rated stocks.

What is Clovis Oncology's stock price forecast for 2023?

2 brokers have issued 12-month target prices for Clovis Oncology's stock. Their CLVS share price forecasts range from $5.00 to $5.00. On average, they anticipate the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 6,150.0% from the stock's current price.
View analysts price targets for CLVS or view top-rated stocks among Wall Street analysts.

When is Clovis Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our CLVS earnings forecast.

How were Clovis Oncology's earnings last quarter?

Clovis Oncology (NASDAQ:CLVS) issued its quarterly earnings data on Wednesday, November, 9th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.03. The biopharmaceutical company had revenue of $30.66 million for the quarter, compared to the consensus estimate of $34.79 million.

What is Patrick J. Mahaffy's approval rating as Clovis Oncology's CEO?

12 employees have rated Clovis Oncology Chief Executive Officer Patrick J. Mahaffy on Glassdoor.com. Patrick J. Mahaffy has an approval rating of 49% among the company's employees. This puts Patrick J. Mahaffy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Clovis Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Tesla (TSLA), Amarin (AMRN), Intercept Pharmaceuticals (ICPT), Netflix (NFLX) and Alibaba Group (BABA).

What is Clovis Oncology's stock symbol?

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

Who are Clovis Oncology's major shareholders?

Clovis Oncology's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bank of Montreal Can (0.00%), Wolverine Asset Management LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Daniel W Muehl, Gillian C Ivers-Read, Lindsey Rolfe, Paul Edward Gross, Thomas C Harding and Thomas C Harding.
View institutional ownership trends.

What is Clovis Oncology's stock price today?

One share of CLVS stock can currently be purchased for approximately $0.08.

How much money does Clovis Oncology make?

Clovis Oncology (NASDAQ:CLVS) has a market capitalization of $11.60 million and generates $148.76 million in revenue each year. The biopharmaceutical company earns $-264,520,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis.

How can I contact Clovis Oncology?

Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The official website for the company is www.clovisoncology.com. The biopharmaceutical company can be reached via phone at 303-625-5000, via email at bburkart@clovisoncology.com, or via fax at 303-245-0360.

This page (NASDAQ:CLVS) was last updated on 2/2/2023 by MarketBeat.com Staff